期刊文献+

人补体C1INH基因的原核表达及其抗血清的制备

Prokaryotic Expression of Human C1 Inhibitor and Its Antiserum Preparation
下载PDF
导出
摘要 采用PCR技术获得人补体C1INH基因全长,以其为模板扩增出抗原表位基因片段命名为C1,然后将C1片段重组到pET32a(+)载体中,筛选阳性克隆,转化大肠杆菌;IPTG诱导表达,用超声波裂解重组菌BL21培养物,纯化蛋白后免疫新西兰兔制备抗血清。SDS-PAGE分析表明,pET32a-C1融合蛋白在大肠杆菌BL21(DE3)菌株中以包涵体形式高效表达;获得的抗血清经间接ELISA法检测效价为1∶6 400;Western-blot检测显示,抗血清可与原核表达的C1INH蛋白进行特异性结合,为进一步检测真核表达蛋白及研究rhC1INH的功能活性,并为C1INH的临床检测奠定基础。 The complete gene of human C1INH by gene cloning techniques was obtained and C1INH was chosen as templates to obtain the fragment of hC1INH which was named as C1,then cloning the fragment C1 into pET32a(+) vector,and screening positive cloning.Transform the recombinant plasmid into E.coli BL21(DE3) and induce it with IPTG for expressing;split the recombinant strain culture solution and purify the fusion protein and immunize the New Zealand rabbits so as to prepare the antisera.SDS-PAGE analysis showed that pET32a-C1 was expressed in the form of inclusion bodies in E.coli BL21(DE3);The titer of the rabbit antibody which prepared by pET32a-C1 was 1:6400;Western-blot analysis showed that the antisera could bind to C1INH protein of prokaryotic expression specifically,which laid a foundation for further study on the detection of C1INH expression in the eukaryotic syetem and its function,as well as for the clinical research of human complement C1INH.
出处 《家畜生态学报》 北大核心 2012年第2期8-12,30,共6页 Journal of Domestic Animal Ecology
基金 国家自然科学基金(31072160) 泰山学者海外特聘专家(何洪彬) 国家转基因重大专项(2009ZX08007-006B 2011ZX08007-002) 国家奶牛产业技术体系建设专项经费(何洪彬) 济南市高校院所自主创新计划(201004027 201102034)
关键词 人补体C1INH 原核表达 抗血清 human complement C1 inhibitor prokaryotic expression antiserum
  • 相关文献

参考文献17

  • 1Coutinho M, Aulak KS, Davis AE. Function alanalysis of the serpin domain of inhibitor[J]. J Immunol, 1994,153: 3 648-3 654.
  • 2Choi G, Soeter M R. Recombinant human Cl-inhibitor in the treatment of acute angioedema attacks[J].Transfusion, 2007, 47(6):1 028-1 032.
  • 3Fay A, Abinun M. Current management of hereditary angio oedema (Clsterase inhibitor deficiency)[J].J Clin Pathol, 2002, 55:266-270.
  • 4Hack C E, Voerman H J, Eisele B,et al. Cl-esterase inhibitor substitution in sepsis[J].Lancet, 1992,339:378.
  • 5Hack C E, Ogilvie A C, Eisele B,et al. Cl-inhibitor substitu tion therapy in septic shock and in the vascular leak syndrome induced by high doses of interleukin 2 [J].Intensive Care Med, 1993,19 (S1) : 19-28.
  • 6Liu D, Gu X, Scafidi J, et al. N-linked glycosylation is re quired for C1 inhibitor-mediated protection from endotoxin shock in mice[J]. Infect Immun, 2004,72 : 1 946-1 955.
  • 7Guerrero R, Velasco F, Rodriguez M, et al. Endotoxin-indueed pulmonary dysfunetion is prevented by C1 esterase inhibitor[J]. J Clin Invest, 1993,91 : 2 754-2 760.
  • 8Fengxin Lu,Anil K, Chauhan. The effect of C1 inhibitor on intestinal isehemia and reperfusion injury[J].Am J Physiol Gastrointest Liver Physiol, 2008,295:1 042-1 049.
  • 9Akita N, Nakase H, Kaido T,et al. Protective effect of C1 esterase inhibitor on reperfusion injury in the rat middle cerebral artery occlusion model[J]. Neurosurgery, 2003,52 : 395 -400.
  • 10Gailani D, Renne T. The intrinsic pathway of coagulation: a target for treating thromboembolic disease [J ]. J Thromb Haemost, 2007,5:1 106-1 112.

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部